WHO: Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV
![Immagine News](/media/cnyhiizm/cat-4.jpg?anchor=center&mode=crop&width=722&height=442)
These guidelines update the recommendations that were first released in 2018 on diagnosing, preventing, and managing cryptococcal disease. In response to important new evidence that became available in 2021, these new guidelines strongly recommend a single high dose of liposomal amphotericin B as part of the preferred induction regimen for the treatment of cryptococcal meningitis in people living with HIV. This simplified regimen - a single high dose of liposomal amphotericin B paired with other standard medicines (flucytosine and fluconazole) - is as effective as the previous WHO standard of care, with the benefits of lower toxicity and fewer monitoring demands.
Additional details to the following link: https://www.who.int/publications/i/item/9789240052178